Literature DB >> 30151084

Synthesis and evaluation of 6-heteroarylamino-2,4,5-trimethylpyridin-3-ols as inhibitors of TNF-α-induced cell adhesion and inflammatory bowel disease.

Sang Won Park1, Suhrid Banskota2, Pallavi Gurung2, You Jin Jin1, Han-Eol Kang1, Chhabi Lal Chaudhary2, Sang Yeul Lee1, Byeong-Seon Jeong2, Jung-Ae Kim2, Tae-Gyu Nam1.   

Abstract

Inflammatory bowel disease (IBD) is an inflammatory disease of the gastrointestinal tract with complex pathogenesis. Here, we synthesized 6-heteroarylamino analogues to inhibit TNF-α-induced adhesion of monocytes to colon epithelial cells which are implicated in the initial inflammation process of IBD. The best analogue, 16a, showed IC50 = 0.29 μM, which is about five orders of magnitude better than that of 5-aminosalicylic acid (5-ASA), a positive control. Oral administration of 6f and 16a dramatically ameliorated 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colon inflammation in rat. The ameliorating effects were accompanied by a high level of recovery in colon and body weights and in the myeloperoxidase (MPO) level. Consistently, the compounds suppressed the expression of intercellular adhesion molecule-1 (ICAM-1) and monocyte chemoattractant protein 1 (MCP-1). Moreover, they significantly suppressed the expression of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 while increasing the level of IL-10, an anti-inflammatory cytokine.

Entities:  

Year:  2018        PMID: 30151084      PMCID: PMC6096353          DOI: 10.1039/c8md00156a

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  29 in total

Review 1.  The global burden of IBD: from 2015 to 2025.

Authors:  Gilaad G Kaplan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-09-01       Impact factor: 46.802

2.  6-Amino-2,4,5-trimethylpyridin-3-ols: a new general synthetic route and antiangiogenic activity.

Authors:  Dong-Guk Kim; Youra Kang; Hyunji Lee; Eun Kyung Lee; Tae-gyu Nam; Jung-Ae Kim; Byeong-Seon Jeong
Journal:  Eur J Med Chem       Date:  2014-03-17       Impact factor: 6.514

Review 3.  Integrins and adhesion molecules as targets to treat inflammatory bowel disease.

Authors:  Ivana Bravatà; Mariangela Allocca; Gionata Fiorino; Silvio Danese
Journal:  Curr Opin Pharmacol       Date:  2015-12       Impact factor: 5.547

Review 4.  IL-10: the master regulator of immunity to infection.

Authors:  Kevin N Couper; Daniel G Blount; Eleanor M Riley
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

5.  Protective effect of 7-O-succinyl macrolactin A against intestinal inflammation is mediated through PI3-kinase/Akt/mTOR and NF-κB signaling pathways.

Authors:  Sumin Park; Sushil Chandra Regmi; Su-Young Park; Eun Kyoung Lee; Jae-Hoon Chang; Sae Kwang Ku; Dong-Hee Kim; Jung-Ae Kim
Journal:  Eur J Pharmacol       Date:  2014-04-24       Impact factor: 4.432

Review 6.  New drugs on the horizon for IBD.

Authors:  Bruce E Sands
Journal:  Dig Dis       Date:  2014-12-17       Impact factor: 2.404

7.  In vitro and in vivo inhibitory activity of 6-amino-2,4,5-trimethylpyridin-3-ols against inflammatory bowel disease.

Authors:  Suhrid Banskota; Han-Eol Kang; Dong-Guk Kim; Sang Won Park; Hyeonjin Jang; Ujjwala Karmacharya; Byeong-Seon Jeong; Jung-Ae Kim; Tae-Gyu Nam
Journal:  Bioorg Med Chem Lett       Date:  2016-08-24       Impact factor: 2.823

8.  Design and synthesis of 5-[(2-chloro-6-fluorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole (AKP-001), a novel inhibitor of p38 MAP kinase with reduced side effects based on the antedrug concept.

Authors:  Koichi Hasumi; Shuichiro Sato; Takahisa Saito; Jun-ya Kato; Kazuhiko Shirota; Jun Sato; Hiroyuki Suzuki; Shuji Ohta
Journal:  Bioorg Med Chem       Date:  2014-06-03       Impact factor: 3.641

Review 9.  Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target.

Authors:  Mariangela Allocca; Manol Jovani; Gionata Fiorino; Stefan Schreiber; Silvio Danese
Journal:  Curr Drug Targets       Date:  2013-11       Impact factor: 3.465

10.  Clotrimazole ameliorates intestinal inflammation and abnormal angiogenesis by inhibiting interleukin-8 expression through a nuclear factor-kappaB-dependent manner.

Authors:  Dinesh Thapa; Jong Suk Lee; Su-Young Park; Yun-Hee Bae; Soo-Kyung Bae; Jun Bum Kwon; Kyoung-Jin Kim; Mi-Kyoung Kwak; Young-Joon Park; Han Gon Choi; Jung-Ae Kim
Journal:  J Pharmacol Exp Ther       Date:  2008-08-26       Impact factor: 4.030

View more
  2 in total

1.  Synthesis, activity and mechanism of alkoxy-, carbamato-, sulfonamido-, thioureido-, and ureido-derivatives of 2,4,5-trimethylpyridin-3-ol against inflammatory bowel disease.

Authors:  Chhabi Lal Chaudhary; Pallavi Gurung; Seoul Jang; Suhrid Banskota; Tae-Gyu Nam; Jung-Ae Kim; Byeong-Seon Jeong
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

2.  Synthesis of Pyridoxine-Derived Dimethylpyridinols Fused with Aminooxazole, Aminoimidazole, and Aminopyrrole.

Authors:  Bhuwan Prasad Awasthi; Hyunji Lee; Byeong-Seon Jeong
Journal:  Molecules       Date:  2022-03-23       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.